Editors Note: This article discusses one or more penny stocks/microcaps. Such stocks are readily manipulated; do your own careful due diligence. 

100 clinical-stage psychedelic drug stocks (see here) research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (see here) but only 8 have market caps of $50M or more, and trade for US$0.50/share or more, and they are tracked in the munKNEE  Psychedelic Compounds-Based Drug Stocks Index.

Psychedelic Compounds-Based Drug Stocks Index

Below is the stock price performance of each of the 8 constituents last week, in descending order, and in the last 5 weeks (since the end of May) and YTD (as of July 8th):

1. Seelos (SEEL): +39.7% last week; +53.2% in last 5 weeks; -41.7% YTD
   • focused on developing products that address significant unmet needs in Central Nervous System disorders and other rare disorders.
     • *Altman-Z Score: 44% chance of financial distress in the next 2 years
     • **Piotroski F Score: 3
2. GH Resources (GHRS): +28.8% last week; +33.6% in the last 5 weeks; -44.9% YTD
   • focused on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
     • *Altman-Z Score: 58% chance of financial distress in the next 2 years
     • **Piotroski F Score: 3
3. Compass Pathways (CMPS): +25.8% last week; +61.8% in last 5 weeks; -38.4% YTD
   • focused on the development of a new model of psilocybin therapy for people with treatment-resistant depression, in which psilocybin is administered in conjunction with psychological support.
     • *Altman-Z Score: 24% chance of financial distress in the next 2 years
     • **Piotroski F Score: 2
4. Atai (ATAI): +18.4% last week; +5.9% in the last 5 weeks; -43.5% YTD
   • focused on acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
     • *Altman-Z Score: 12.2; 53% chance of financial distress in the next 2 years
     • **Piotroski F Score: 5
5. Cybin (CYBN): +12.5% last week; -3.1% in the last 5 weeks; -47.5% YTD 
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
     • *Altman-Z Score: 60% chance of financial distress in the next 2 years
     • **Piotroski F Score: 0
6. Mind Medicine (MNMD): +7.8% last week; -20.7% in the last 5 weeks; -50.0% YTD
   • focused on discovering, developing, and deploying the next generation of psychedelic-inspired medicines and therapies to address addiction and mental illness development.
     • *Altman-Z Score: 62% chance of financial distress in the next 2 years
     • **Piotroski F Score: 3
7. Zynerba (ZYNE): No Change last week; +16.3% in the last 5 weeks; -60.4% YTD
   • focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.
     • *Altman-Z Score: 6% chance of financial distress in the next 2 years
     • **Piotroski F Score: 3
8. Allied Corp. (ALID): -2.1% last week; -35.6% in the last 5 weeks; -73.4% YTD
   • focused on the research, development, and production of cannabinoid health solutions in the United States and has a product in Phase I clinical trial in Columbia for treating post-traumatic stress disorder
     • *Altman-Z Score: 38% chance of financial distress in the next 2 years
     • **Piotroski F Score: 3

*The Altman-Z Score is a numerical measurement used to predict the chances of a business going bankrupt in the next two years based on five financial ratios - profitability, leverage, liquidity, solvency, and activity and has an accuracy that ranges from 82% and 94%. 

**The Piotroski F Score is a back-tested strategy that rates how strong the financial fundamentals are for a value stock and in back-testing of the system against the market between 1976 and 1996 the system it would have beaten the average return on the stock market by 13.4%.

• A score of 0-3 indicates that the company has weak fundamentals while a score of 8-9 indicates a company with powerful fundamentals that are most likely to keep performing well in the future.
• The Piotroski F Score is 100% accurate from a technical perspective yet unforeseen events like an economic downturn, for example, can cause the markets to plummet regardless of what model is used. The Piotroski F Score is no exception but, ignoring any extreme situations, there is likely quite a lot of merit to the Piotroski F Score.

In total, the munKNEE Psychedelic Compounds-Based Drug Stocks Index was +24.0% last week; +33.5% in the last 5 weeks; but still -44.0% YTD.

More By This Author:

Canadian Pot Stocks Index Up Last Week; Still Down YTD
Check Out These 3 Financial Metrics Before Buying A Cannabis Stock
Summary: Performance Of These 10 Categories Varied Greatly In June And YTD